ACRIN 6687, a multi-center clinical trial evaluating differential response of bone metastases to dasatinib in men with metastatic castration-resistant prostate cancer (mCRPC), used [18F]-fluoride (NaF) PET imaging. We extend previous ACRIN 6687 dynamic imaging results by examining NaF whole-body (WB) static SUV PET scans acquired after dynamic scanning. Eighteen patients underwent WB NaF imaging prior to and 12 weeks into dasatinib treatment. Regional VOI analysis of the most NaF avid bone metastases and an automated whole-body method using Quantitative Total Bone Imaging software (QTBI; AIQ Solutions, Inc., Madison, WI, USA) were used. We assessed differences in tumor and normal bone, between pre- and on-treatment dasatinib, and evaluated parameters in association with PFS and OS. Significant decrease in average SUVmax and average SUVpeak occurred in response to dasatinib. Univariate and multivariate analysis showed NaF uptake had significant association with PFS. Pharmacodynamic changes with dasatinib in tumor bone can be identified by WB NaF PET in men with mCRPC. WB PET has the benefit of examining the entire body and is less complicated than single FOV dynamic imaging.
Tomography (Ann Arbor, Mich.). 2021 Apr 25*** epublish ***
Mark Muzi, Finbarr O'Sullivan, Timothy G Perk, John P Muzi, David A Mankoff, Robert Jeraj, Fenghai Duan, Evan Y Yu
School of Medicine, University of Washington, Seattle, WA 98195, USA., School of Mathematical Sciences, University College, T12 XF62 Cork, Ireland., AIQ Solutions, Madison, WI 53717, USA., Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA., Department of Medical Physics, University of Wisconsin, Madison, WI 53705, USA., Department of Biostatistics, Brown University, Providence, RI 02912, USA.